このアイテムのアクセス数: 288
このアイテムのファイル:
| ファイル | 記述 | サイズ | フォーマット | |
|---|---|---|---|---|
| 16_0489.pdf | 4.38 MB | Adobe PDF | 見る/開く |
| タイトル: | 19-norhydroxyprogesterone caproate(SH-582)による前立腺肥大症の治療について |
| その他のタイトル: | Treatment of prostatic hypertrophy with 19-norhydroxyprogesterone caproate |
| 著者: | 加藤, 篤二  岡田, 謙一郎 |
| 著者名の別形: | Kato, Tokuji Okada, Ken-ichiro |
| キーワード: | Aged Animals Caproates/pharmacology/therapeutic use Humans Injections, Intramuscular Male Middle Aged Organ Size Pregnanes/pharmacology/therapeutic use Prostate/drug effects/pathology Prostatic Hyperplasia/drug therapy Rats Seminal Vesicles/drug effects/pathology Testis/drug effects/pathology |
| 発行日: | Sep-1970 |
| 出版者: | 京都大学医学部泌尿器科学教室 |
| 誌名: | 泌尿器科紀要 |
| 巻: | 16 |
| 号: | 9 |
| 開始ページ: | 489 |
| 終了ページ: | 500 |
| 抄録: | 1) SH-582 was used in 25 cases of prostatic hypertrophy over an average period of 5 months. Clinical symptoms were improved in 60 to 70 % of those cases. 2) Animal experiments in rats demonstrated an atrophy of the ventral lobe of the prostate. 3) It was presumed that the effects of SH•582 in reducing the prostate might be ascribable to its inhibitory action not on the central but on the peripheral system, or, to be more accurate, on the prostate itself. 4) There were no severe side-effects following administration of SH-582. However, great care should be taken when patients having complications of diabetes or hepatic disturbances are treated with SH-582. |
| URI: | http://hdl.handle.net/2433/121163 |
| PubMed ID: | 4097361 |
| 出現コレクション: | Vol.16 No.9 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。